Livzon Pharmaceutical Group Inc. researches, develops, produces, exports, and sells pharmaceutical products, active pharmaceutical ingredients (APIs), and intermediates in China and internationally. Its product portfolio includes treatments for assisted reproduction, gastrointestinal, psychiatric, and neurological fields, as well as traditional Chinese medicines. The company also manufactures APIs and intermediates, and offers diagnostic reagents and kits, including tests for infectious diseases and autoimmune conditions. Incorporated in 1985, Livzon Pharmaceutical Group is headquartered in Zhuhai, China.
Why is Livzon Pharmaceutical Group Inc (000513.CS) moving?
Latest
▲2▼1
Livzon profit slumps on price cuts, but new drug approvals build pipeline
▼
First-half profit and revenue drop sharply Livzon's first-half net profit fell 27.2% to 932 million yuan and revenue dropped 20.3% to 5 billion yuan. Chemical drug sales fell 25% on medical insurance price cuts and national volume-based procurement, while TCM sales fell 35% as flu demand faded. This weak earnings picture is the main drag on the stock.
The profit decline is the single biggest force pushing the stock down this period.
New leuprorelin three-month microsphere approval Shanghai Livzon won approval for an 11.25mg three-month leuprorelin acetate microsphere injection, a Category B insurance-listed drug for breast cancer, prostate cancer and precocious puberty. It is the only domestic maker of this dosage form, in a market worth about 10.9 billion yuan where three-month forms are 27%.
A genuinely new, exclusive product approval that can add future revenue and offsets the weak earnings.
New TCM granule approval enriches product line Livzon's Sichuan Guangda unit received a drug registration certificate for Banxia Baizhu Tianma Decoction Granules, its first Category 3.1 new traditional Chinese medicine. The approval adds to the product pipeline, though the company gave no launch timing or sales forecast, so the near-term financial benefit is limited.
A new product approval that supports the pipeline story, though small in scale.
Parent Joincare's weak finances and guarantee load Parent Joincare disclosed a 2.069 billion yuan guarantee balance, including guarantees for Livzon units, while its 2025 and first-quarter revenue and profit both fell. This adds a modest financial-risk overhang, though the guarantees are not overdue and Livzon's own operating cash flow actually rose 4.5%.
Shows the parent-level financial backdrop and guarantee exposure that color sentiment on Livzon.
Joincare Subsidiary's Leuprorelin Acetate Microspheres for Injection 11.25mg Approved for Market
Joincare announced that Shanghai Livzon, under its controlling subsidiary Livzon Group, has received the Drug Supplementary Application Approval Notice issued by the National Medical Products Administration. Leuprorelin acetate microspheres for injection 11.25mg, a three-month dosage form, has been approved for market. The drug is a Category B product in the National Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance Drug List, with indications including premenopausal breast cancer, prostate cancer and central precocious puberty. To date, cumulative R&D investment in the drug is approximately 94.05 million yuan. Domestically, only Shanghai Livzon holds the approval for this dosage form, excluding the originator. In 2025, terminal sales of long-acting GnRHa sustained-release formulations in China were approximately 10.9 billion yuan, of which the three-month dosage form accounted for 27%.
Livzon Group Vice President Xu Xiao Resigns Due to Work Reassignment
Livzon Group announced that its board of directors received a written resignation report from Vice President Xu Xiao on September 23, 2026. Due to work reassignment arrangements, Xu Xiao applied to resign from the position of vice president, and will continue to hold other positions in the company after stepping down. The resignation report takes effect from the date it is delivered to the board of directors and will not affect the company's normal production and operations. As of the disclosure date of the announcement, Xu Xiao did not hold any company shares, and there were no commitments that should have been fulfilled but had not been fulfilled.
000513.CS · · Neutral Vice President Xu Xiao resigns due to work reassignment but stays in other roles; company says operations unaffected, no clear driver.
Livzon Group's 2026 Interim Net Profit Falls 27.23% to 932 Million Yuan
Livzon Group released its 2026 interim report, with net profit attributable to the parent company at 932 million yuan, down 27.23% from the same period last year. Total operating revenue was 5 billion yuan, down 20.28% year-on-year. Net cash inflow from operating activities was 1.763 billion yuan. The latest asset-liability ratio was 38.12%, gross margin was 61.28%, ROE was 6.97%, and diluted earnings per share was 1.05 yuan.
Livzon Group first-half net profit attributable to parent falls 27.2% to 932 million yuan
Livzon Group released its 2026 half-year report, showing first-half net profit attributable to the parent of 932 million yuan, down 27.2% year on year. Operating revenue was 5.0 billion yuan, down 20.3% year on year. Net profit attributable to the parent excluding non-recurring items was 890 million yuan, down 29.3% year on year. Net operating cash flow was 1.763 billion yuan, up 4.5% year on year. Second-quarter operating revenue was 2.13 billion yuan, down 31.1% year on year, and net profit attributable to the parent was 355 million yuan, down 44.9% year on year. The company said sales revenue from its chemical preparations business fell 25.33% due to medical insurance price cuts and national volume-based procurement. Sales revenue from traditional Chinese medicine preparations and other business segments fell 34.83%, mainly because the incidence of influenza and respiratory diseases declined in the first quarter, reducing demand for related products.
Livzon Group to acquire 3.5044% stake in Xinbeijiang Pharmaceutical for 107 million yuan
Livzon Group announced plans to spend 107 million yuan to acquire a 3.5044% stake in Xinbeijiang Pharmaceutical. On August 21, Livzon Group issued an announcement stating that the company signed a share transfer agreement with Zhuhai Zhonghuiyuan Investment Partnership and Xinbeijiang Pharmaceutical Co., Ltd., under which it intends to purchase the 3.5044% stake in Xinbeijiang Pharmaceutical held by Zhonghuiyuan. After the transaction is completed, Livzon Group will hold 90.6443% of Xinbeijiang Pharmaceutical, while Zhonghuiyuan will hold 4.9324%. Xinbeijiang Pharmaceutical is a controlling subsidiary of Livzon Group and will continue to be included in the company's consolidated financial statements. In the first half of 2026, Livzon Group achieved revenue of 5 billion yuan and net profit attributable to the parent company of 932 million yuan.
Joincare discloses guarantee balance of 2.069 billion yuan as annual and quarterly reports show declines in both revenue and net profit
Joincare disclosed that as of July 31, 2026, its total guarantee balance stood at 2.069 billion yuan, accounting for 13.63% of its latest audited net assets. This includes 1.842 billion yuan in guarantees for wholly owned and controlled subsidiaries, and 227 million yuan in guarantees for its joint venture Jinguan Electric Power, with no overdue external guarantees. In July 2026, the company and its controlled subsidiary Livzon Pharmaceutical Group signed multiple guarantee contracts with China Merchants Bank, ICBC, and Bank of Communications, involving entities such as Joincare Haibin Pharmaceutical, Jiaozuo Joincare Biological Products, Shenzhen Taitai Pharmaceutical, Xinxiang Haibin Pharmaceutical, Livzon Group Livzon Pharmaceutical Factory, Sichuan Guangda Pharmaceutical, Zhuhai Livzon Pharmaceutical Trading, Livzon Group Ningxia Pharmaceutical, Livzon Group New Beijiang Pharmaceutical, and Jiaozuo Livzon Synthetic Pharmaceutical. Individual guarantee amounts ranged from 30 million yuan to 302 million yuan. The company's 2025 revenue was 15.216 billion yuan, down 2.58% year-on-year, with net profit attributable to shareholders of 1.336 billion yuan, down 3.68% year-on-year, marking the third time in recent years that both revenue and net profit declined. In the first quarter of 2026, revenue was 3.721 billion yuan, down 8.99% year-on-year, and net profit attributable to shareholders was 415 million yuan, down 4.78% year-on-year. As of the close on August 4, the company's stock had fallen nearly 12% for the year.
600380.CG · Capital · Negative Revenue and net profit declined in 2025 and Q1 2026, with stock down nearly 12% for the year.
000513.CS · Capital · Negative As a controlled subsidiary, its parent's financial declines and guarantee disclosures reflect negatively on its performance.
Joincare Subsidiary Obtains Drug Registration Certificate for Banxia Baizhu Tianma Decoction Granules
Joincare announced that its controlled subsidiary, Livzon Group's subsidiary Sichuan Guangda Pharmaceutical, has received a Drug Registration Certificate issued by the National Medical Products Administration, approving the market launch of Banxia Baizhu Tianma Decoction Granules. This drug is a Category 3.1 new traditional Chinese medicine, the company's first approved Category 3.1 new TCM drug, which will further enrich the company's product pipeline. As of the announcement date, the cumulative R&D investment for this drug was approximately 5.01 million yuan.
Livzon Group Subsidiary Obtains Drug Registration Certificate for Banxia Baizhu Tianma Decoction Granules
Livzon Group announced that its subsidiary Sichuan Guangda Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Banxia Baizhu Tianma Decoction Granules issued by the National Medical Products Administration. The drug registration application has been approved, but the specific indications and market impact have not been disclosed in detail in the announcement. Livzon Group stated that this approval will enrich the company's product line, but did not reveal the expected launch time or sales forecast.
China